Glycoconjugate Journal

, Volume 13, Issue 3, pp 391–399 | Cite as

In vivo growth conditions suppress the expression of ganglioside GM2 and favour that of lacto series gangliosides in the human glioma D-54MG cell line

  • Pam Fredman
  • Carol J Wikstrand
  • Jan-Eric Månsson
  • Guido Reifenberger
  • Sandy H Bigner
  • Ahmed Rasheed
  • Lars Svennerholm
  • Darell D Bigner
Papers Dedicated To Dr Sen-Itiroh Hakomori

Abstract

The human glioma D-54MG cell line grownin vitro primarily expresses ganglio series gangliosides, particularly GM2. Subcutaneous injection of these cells into nude mice produced xenografts with an increased content of the human glioma-associated lacto series gangliosides, primarily 3′-isoLM1, an alteration that was dose dependent, with the highest dose (1×108) resulting in a phenotype that was most like that of the inoculum. After one passagein vivo, the lacto series dominated and reached a proportional level that was kept throughout the 10 passages. The mRNA levels of the GM2-synthase clearly coincided with GM2 expression and was 20 times higher in cells grownin vitro than in those grownin vivo. These results support the view that ganglioside expression in human gliomas is strongly influenced by environmental factors.

Keywords

Ganglioside antigens gliomas ganglioside metabolism glioma cell line 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Månsson J-E, Fredman P, Bigner DD, Molin K, Rosengren B, Friedman HS, Svennerholm L (1986)FEBS Lett 201: 109–13.Google Scholar
  2. 2.
    Fredman P (1993)Brain Res 101: 225–40.Google Scholar
  3. 3.
    Wikstrand CJ, He X, Fuller GN, Bigner SH, Fredman P, Svennerholm L, Bigner DD (1991)J Neuropath Exp Neurol 50: 756–69.Google Scholar
  4. 4.
    Wikstrand CJ, Longee DC, McLendon RE, Fuller GN, Friedman HS, Fredman P, Svennerholm L, Bigner DD (1993)Cancer Res 53: 120–26.Google Scholar
  5. 5.
    Fredman P, von Holst H, Collins VP, Dellheden B, Svennerholm L (1993)J Neuro Chem 60: 99–105.Google Scholar
  6. 6.
    Svennerholm L, Boström K, Fredman P, Månsson J-E, Rosengren B, Rynmark B-M (1989)Biochim Biophys Acta 1005: 109–17.Google Scholar
  7. 7.
    Gottfries J, Fredman P, Månsson J-E, Hansson E, Svennerholm L (1991)Neuro Chem Int 19: 227–33.Google Scholar
  8. 8.
    Marienhagen K, Pedersen PH, Terzis AJ, Laerum OD, Arnold H, Bjerkvig R (1994)Neuropathol Appl Neurobiol 20: 130–43.Google Scholar
  9. 9.
    Bernstein JJ, Woodward CA (1995)Neurosurgery 36: 124–32.Google Scholar
  10. 10.
    Bjerkvig R, Engebraaten O, Laerum OP, Fredman P, Svennerholm L, Bigner DD (1991)Cancer Res 51: 4643–48.Google Scholar
  11. 11.
    Fredman P, Nilsson O, Tayot J-L, Svennerholm L (1980)Biochim Biophys Acta 618: 42–52.Google Scholar
  12. 12.
    Månsson J-E, Mo H, Egge H, Svennerholm L (1986)FEBS Lett 196: 259–62.Google Scholar
  13. 13.
    Vrionis F, Wikstrand CJ, Fredman P, Månsson J-E, Svennerholm L, Bigner DD (1989)Cancer Res 49: 6645–51.Google Scholar
  14. 14.
    Månsson J-E, Fredman P, Nilsson O, Lindholm L, Holmgren J, Svennerholm L (1985)Biochim Biophys Acta 834: 110–17.Google Scholar
  15. 15.
    Longee DC, Wikstrand CJ, Månsson J-E, He X, Fuller GN, Bigner SH, Fredman P, Svennerholm L, Bigner DD (1991)Acta Neuropath 82: 45–54.Google Scholar
  16. 16.
    He X, Wikstrand CJ, Fredman P, Månsson J-E, Svennerholm L, Bigner DD (1989)Acta Neuropathol 79: 317–25.Google Scholar
  17. 17.
    Fredman P, Jeansson S, Lycke E, Svennerholm L (1985)FEBS Lett 189: 23–26.Google Scholar
  18. 18.
    Lindholm L, Holmgren J, Wikström J, Karlsson U, Andersson K, Lycke N (1983)Infect Immunol 40: 570–76.Google Scholar
  19. 19.
    Giard DJ, Aaronson SA, Todaro GJ, Arnstein P, Kersey JH, Dosik H, Parks WP (1973)J Natl Cancer Inst 51: 1417–23.Google Scholar
  20. 20.
    Bigner DD, Bigner SH, Pontén J, Westermark B, Mahaley MS, Ruoslathi E, Herschman H, Eng LF, Wikstrand CJ (1981)J Neuropath Exp Neurol 40: 201–29.Google Scholar
  21. 21.
    Wikstrand CJ, Bigner SH, Bigner DD (1983)Cancer Res 43: 3327–34.Google Scholar
  22. 22.
    Schold SC, Bullard DE, Bigner SH, Jones TR, Bigner DD (1983)J Neurooncol 1: 5–14.Google Scholar
  23. 23.
    Bigner SH, Bullard DE, Pegram CE, Wikstrand CJ (1981)J Neuropath Exp Neurol 40: 390–409.Google Scholar
  24. 24.
    Wikstrand CJ, McLendon RE, Carrel S, Kemshead JT, Mach JP, Coakham HB, de Tribolet N, Bullard DE, Zalutsky MR, Bigner DD (1987)J Neuroimmunol 15: 37–56.Google Scholar
  25. 25.
    Friedman HS, Schold SC, Varia M, Bigner DD (1983)Cancer Res 43: 3088–93.Google Scholar
  26. 26.
    Fredman P, Månsson J-E, Bigner SH, Mark J, Wikstrand CJ, Bigner DD, Svennerholm L (1990)Biochim Biophys Acta 1045: 239–44.Google Scholar
  27. 27.
    Smith PK, Krohn RI, Hermansson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ, Klenk DC (1985)Analy Biochem 150: 76–85.Google Scholar
  28. 28.
    Davidsson P, Fredman P, Månsson J-E, Svennerholm L (1991)Clin Chim Acta 197: 105–16.Google Scholar
  29. 29.
    Gottfries J, Percy AK, Månsson J-E, Fredman P, Wikstrand CJ, Friedman HS, Bigner DD, Svennerholm L (1991)Biochim Biophys Acta 1081: 253–61.Google Scholar
  30. 30.
    Momoi T, Shinmoto M, Kasuya J, Senoo H, Suzuki Y (1986)J Biol Chem 261: 16270–73.Google Scholar
  31. 31.
    Sambrook J, Fritsch EG, Maniatis T (eds) (1989) In:Molecular Cloning A Laboratory Manual. 2nd edition, pp. 5.2–5.95.Google Scholar
  32. 32.
    Ekstrand AJ, James CD, Cavenee WK, Seliger B, Pettersson RF, Collins VP (1991)Cancer Res 51: 2164–72.Google Scholar
  33. 33.
    Nagata Y, Yamashiro S, Yodoi J, Lloyd KO, Shiku H, Furukawa K (1992)J Biol Chem 267: 12082–89.Google Scholar
  34. 34.
    Gottfries J, Fredman P, Månsson J-E, Collins VP, von Holst H, Armstrong DD, Percy AK, Wikstrand C, Bigner DD, Svennerholm L (1990)J Neurochem 55: 1322–26.Google Scholar
  35. 35.
    Tsuchida T, Ravindranath MH, Saxton RE, Irie RF (1987)Cancer Res 47: 1278–81.Google Scholar
  36. 36.
    van Echten G, Sandhoff K (1993)J Biol Chem 268: 5341–44.Google Scholar
  37. 37.
    Holmes EH, Hakomori S-I, Ostrander GK (1987)J Biol Chem 262: 15649–58.Google Scholar
  38. 38.
    Holmes EH, Greene TG (1990)J Cell Biochem 44: 93–105.Google Scholar
  39. 39.
    Sandhoff K, Klein A (1994)FEBS Lett 346: 103–7.Google Scholar
  40. 40.
    Liepkalns VA, Icard-Liepkalns C, Yates AJ, Mattison S, Stephens RE (1983)J Lipid Res 24: 533–40.Google Scholar
  41. 41.
    Markwell M, Fredman P, Svennerholm L (1984)Biochim Biophys Acta 775: 7–16.Google Scholar
  42. 42.
    Müthing J, Pörtner A, Jäger V (1992)Glycoconjugate J 9: 265–73.Google Scholar

Copyright information

© Chapman & Hall 1996

Authors and Affiliations

  • Pam Fredman
    • 1
  • Carol J Wikstrand
    • 2
  • Jan-Eric Månsson
    • 1
  • Guido Reifenberger
    • 3
  • Sandy H Bigner
    • 2
  • Ahmed Rasheed
    • 2
  • Lars Svennerholm
    • 1
  • Darell D Bigner
    • 2
  1. 1.Institute of Clinical Neuroscience, Department of Psychiatry and NeurochemistryGöteborg University, Mölndal HospitalSweden
  2. 2.Department of Pathology and Preuss Laboratory for Brain Tumor ResearchDuke University Medical CenterDurhamUSA
  3. 3.Department of NeuropathologyHeinrich-Heine UniversityDüsseldorfGermany

Personalised recommendations